false
0001655923
A1
00-0000000
0001655923
2026-11-05
2026-11-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 5, 2026
Alpha Cognition Inc.
(Exact name of registrant as specified in its charter)
| British Columbia |
|
001-42403 |
|
N/A |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification Number) |
1452 Hughes Rd., Ste 200
Grapevine, Texas |
|
76051 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: 858-344-4375
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class: |
|
Trading Symbol |
|
Name of each exchange on which
registered: |
| Common Shares, no par value |
|
ACOG |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange
Act (§240.12b-2 of this chapter).
Emerging growth
company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 5, 2026, the board of directors (the
“Board”) of Alpha Cognition Inc. (the “Company”) appointed Caren Deardorf as a director of the Company effective
November 11, 2026.
Ms. Deardorf is a biotechnology executive and
public company director with more than 30 years of experience spanning commercialization, corporate strategy, portfolio prioritization,
business development, and company building. She has helped organizations create and preserve value through category & brand leadership,
development-to commercial transitions, portfolio decisions, out-licensing, and M&A pathways. Ms. Deardorf is currently Chief Business
and Strategy Officer at Neutrolis Inc., since August of 2025, where she is responsible for leading business development, clinical program
strategy, and commercial/operational build for a private autoimmune company in transition to clinical stage. Prior to that, she served
as Chief Commercial and Strategy Officer at Editas Medicine (2023-2025), Chief Commercial and Strategy Officer at Magenta Therapeutics
(2021-2023) and Chief Commercial Officer at Ohana Biosciences (2019-2021). Ms. Deardorf also recently served on the board of directors
of Crinetics Pharmaceuticals (2022-2026) and NeuroSense Therapeutics (2021-2024). Ms. Deardorf received an M.B.A. from Babson College-
Olin Graduate School of Business and a B.S., Biology (Premed) with French concentration from Tufts University.
Ms. Deardorf will receive compensation in accordance
with the Company’s previously disclosed non-employee director compensation policy.
In accordance with the Company’s non-employee
director annual equity grant, in connection with her appointment, Ms. Deardorf received an initial grant of 755 restricted stock units
and 1,020 stock options. The stock options have an exercise price of $8.62 per share. Both the restricted stock units and the stock options
vest one year after the date of grant.
There is no arrangement or understanding between
Ms. Deardorf and any other persons pursuant to which Ms. Deardorf was appointed as a director. There is no family relationship between
Ms. Deardorf and any director or executive officer of the Company, and except as stated herein, Ms. Deardorf does not have any direct
or indirect material interest in any transaction with the Company or its subsidiaries of the type required to be disclosed pursuant to Item
404(a) of Regulation S-K, and no such transaction is currently contemplated.
Following the appointment of Ms. Deardorf to the
Board, the Board, upon recommendation of its Governance and Nomination Committee, re-constituted its committees as follows:
Compensation Committee
Phillip Mertz (Chair)
Dr. Robert Wills
Kenneth Cawkell
Audit Committee
Bethany Sensenig (Chair)
Dr. Robert Wills
Caren Deardorf
Governance and Nomination Committee
Rajeev “Rob” Bakshi (Chair)
Bethany Sensenig
Caren Deardorf
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ALPHA COGNITION INC. |
| |
|
| |
By: |
/s/ Michael McFadden |
| |
|
Michael McFadden |
| |
|
Chief Executive Officer |
| |
|
|
| Dated: November 12, 2026 |
|